TY - JOUR A1 - Balasubramanian, Srikkanth A1 - Skaf, Joseph A1 - Holzgrabe, Ulrike A1 - Bharti, Richa A1 - Förstner, Konrad U. A1 - Ziebuhr, Wilma A1 - Humeida, Ute H. A1 - Abdelmohsen, Usama R. A1 - Oelschlaeger, Tobias A. T1 - A new bioactive compound from the marine sponge-derived Streptomyces sp. SBT348 inhibits staphylococcal growth and biofilm formation JF - Frontiers in Microbiology N2 - Staphylococcus epidermidis, the common inhabitant of human skin and mucosal surfaces has emerged as an important pathogen in patients carrying surgical implants and medical devices. Entering the body via surgical sites and colonizing the medical devices through formation of multi-layered biofilms leads to refractory and persistent device-related infections (DRIs). Staphylococci organized in biofilms are more tolerant to antibiotics and immune responses, and thus are difficult-to-treat. The consequent morbidity and mortality, and economic losses in health care systems has strongly necessitated the need for development of new anti-bacterial and anti-biofilm-based therapeutics. In this study, we describe the biological activity of a marine sponge-derived Streptomyces sp. SBT348 extract in restraining staphylococcal growth and biofilm formation on polystyrene, glass, medically relevant titan metal, and silicone surfaces. A bioassay-guided fractionation was performed to isolate the active compound (SKC3) from the crude SBT348 extract. Our results demonstrated that SKC3 effectively inhibits the growth (MIC: 31.25 \(\mu\)g/ml) and biofilm formation (sub-MIC range: 1.95-<31.25 \(\mu\)g/ml) of S. epidermidis RP62A in vitro. Chemical characterization of SKC3 by heat and enzyme treatments, and mass spectrometry (HRMS) revealed its heat-stable and non-proteinaceous nature, and high molecular weight (1258.3 Da). Cytotoxicity profiling of SKC3 in vitro on mouse fibroblast (NIH/3T3) and macrophage (J774.1) cell lines, and in vivo on the greater wax moth larvae Galleria mellonella revealed its non-toxic nature at the effective dose. Transcriptome analysis of SKC3 treated S. epidermidis RP62A has further unmasked its negative effect on central metabolism such as carbon flux as well as, amino acid, lipid, and energy metabolism. Taken together, these findings suggest a potential of SKC3 as a putative drug to prevent staphylococcal DRIs. KW - marine sponges KW - Streptomyces KW - Staphylococci KW - device-related infections KW - bioassay-guided fractionation KW - transcriptome Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-221408 VL - 9 ER - TY - JOUR A1 - Bury, Susanne A1 - Soundararajan, Manonmani A1 - Bharti, Richa A1 - von Bünau, Rudolf A1 - Förstner, Konrad U. A1 - Oelschlaeger, Tobias A. T1 - The probiotic escherichia coli strain Nissle 1917 combats lambdoid bacteriophages stx and lambda JF - Frontiers in Microbiology N2 - Shiga toxin (Stx) producing E. coli (STEC) such as Enterohemorrhagic E. coli (EHEC) are the major cause of foodborne illness in humans. In vitro studies showed the probiotic Escherichia coil strain Nissle 1917 (EcN) to efficiently inhibit the production of Stx. Life threatening EHEC strains as for example the serotype 0104:H4, responsible for the great outbreak in 2011 in Germany, evolutionary developed from certain E. coll strains which got infected by stx2-encoding lambdoid phages turning the E. coil into lysogenic and subsequently Stx producing strains. Since antibiotics induce stx genes and Stx production, EHEC infected persons are not recommended to be treated with antibiotics. Therefore, EcN might be an alternative medication. However, because even commensal E. coli strains might be converted into Stx-producers after becoming host to a stx encoding prophage, we tested EcN for stx-phage genome integration. Our experiments revealed the resistance of EcN toward not only stx-phages but also against lambda-phages. This resistance was not based on the lack of or by mutated phage receptors. Rather it involved the expression of a phage repressor (pr) gene of a defective prophage in EcN which was able to partially protect E. coli K-12 strain MG1655 against stx and lambda phage infection. Furthermore, we observed EcN to inactivate phages and thereby to protect E. coli K-12 strains against infection by stx- as well as lambda-phages. Inactivation of lambda-phages was due to binding of lambda-phages to LamB of EcN whereas inactivation of stx-phages was caused by a thermostable protein of EcN. These properties together with its ability to inhibit Stx production make EcN a good candidate for the prevention of illness caused by EHEC and probably for the treatment of already infected people. KW - probiotic KW - E. coli Nissle 1917 KW - EHEC KW - Shiga toxin producing E. coli KW - stx-phages KW - lambda-phages KW - lambdoid prophage KW - LamB Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-221960 VL - 9 ER - TY - JOUR A1 - Allert, Stefanie A1 - Förster, Toni M. A1 - Svensson, Carl-Magnus A1 - Richardson, Jonathan P. A1 - Pawlik, Tony A1 - Hebecker, Betty A1 - Rudolphi, Sven A1 - Juraschitz, Marc A1 - Schaller, Martin A1 - Blagojevic, Mariana A1 - Morschhäuser, Joachim A1 - Figge, Marc Thilo A1 - Jacobsen, Ilse D. A1 - Naglik, Julian R. A1 - Kasper, Lydia A1 - Mogavero, Selene A1 - Hube, Bernhard T1 - \(Candida\) \(albicans\)-Induced Epithelial Damage Mediates Translocation through Intestinal Barriers JF - mBio N2 - Life-threatening systemic infections often occur due to the translocation of pathogens across the gut barrier and into the bloodstream. While the microbial and host mechanisms permitting bacterial gut translocation are well characterized, these mechanisms are still unclear for fungal pathogens such as Candida albicans, a leading cause of nosocomial fungal bloodstream infections. In this study, we dissected the cellular mechanisms of translocation of C. albicans across intestinal epithelia in vitro and identified fungal genes associated with this process. We show that fungal translocation is a dynamic process initiated by invasion and followed by cellular damage and loss of epithelial integrity. A screen of >2,000 C. albicans deletion mutants identified genes required for cellular damage of and translocation across enterocytes. Correlation analysis suggests that hypha formation, barrier damage above a minimum threshold level, and a decreased epithelial integrity are required for efficient fungal translocation. Translocation occurs predominantly via a transcellular route, which is associated with fungus-induced necrotic epithelial damage, but not apoptotic cell death. The cytolytic peptide toxin of C. albicans, candidalysin, was found to be essential for damage of enterocytes and was a key factor in subsequent fungal translocation, suggesting that transcellular translocation of C. albicans through intestinal layers is mediated by candidalysin. However, fungal invasion and low-level translocation can also occur via non-transcellular routes in a candidalysin-independent manner. This is the first study showing translocation of a human-pathogenic fungus across the intestinal barrier being mediated by a peptide toxin. IMPORTANCE Candida albicans, usually a harmless fungus colonizing human mucosae, can cause lethal bloodstream infections when it manages to translocate across the intestinal epithelium. This can result from antibiotic treatment, immune dysfunction, or intestinal damage (e.g., during surgery). However, fungal processes may also contribute. In this study, we investigated the translocation process of C. albicans using in vitro cell culture models. Translocation occurs as a stepwise process starting with invasion, followed by epithelial damage and loss of epithelial integrity. The ability to secrete candidalysin, a peptide toxin deriving from the hyphal protein Ece1, is key: C. albicans hyphae, secreting candidalysin, take advantage of a necrotic weakened epithelium to translocate through the intestinal layer. KW - Candida albicans KW - candidalysin KW - host cell damage KW - host cell invasion KW - intestinal barrier KW - necrosis KW - translocation Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-221084 VL - 9 IS - 3 ER - TY - JOUR A1 - Müller, Laura S. M. A1 - Cosentino, Raúl O. A1 - Förstner, Konrad U. A1 - Guizetti, Julien A1 - Wedel, Carolin A1 - Kaplan, Noam A1 - Janzen, Christian J. A1 - Arampatzi, Panagiota A1 - Vogel, Jörg A1 - Steinbiss, Sascha A1 - Otto, Thomas D. A1 - Saliba, Antoine-Emmanuel A1 - Sebra, Robert P. A1 - Siegel, T. Nicolai T1 - Genome organization and DNA accessibility control antigenic variation in trypanosomes JF - Nature N2 - Many evolutionarily distant pathogenic organisms have evolved similar survival strategies to evade the immune responses of their hosts. These include antigenic variation, through which an infecting organism prevents clearance by periodically altering the identity of proteins that are visible to the immune system of the host1. Antigenic variation requires large reservoirs of immunologically diverse antigen genes, which are often generated through homologous recombination, as well as mechanisms to ensure the expression of one or very few antigens at any given time. Both homologous recombination and gene expression are affected by three-dimensional genome architecture and local DNA accessibility2,3. Factors that link three-dimensional genome architecture, local chromatin conformation and antigenic variation have, to our knowledge, not yet been identified in any organism. One of the major obstacles to studying the role of genome architecture in antigenic variation has been the highly repetitive nature and heterozygosity of antigen-gene arrays, which has precluded complete genome assembly in many pathogens. Here we report the de novo haplotype-specific assembly and scaffolding of the long antigen-gene arrays of the model protozoan parasite Trypanosoma brucei, using long-read sequencing technology and conserved features of chromosome folding4. Genome-wide chromosome conformation capture (Hi-C) reveals a distinct partitioning of the genome, with antigen-encoding subtelomeric regions that are folded into distinct, highly compact compartments. In addition, we performed a range of analyses—Hi-C, fluorescence in situ hybridization, assays for transposase-accessible chromatin using sequencing and single-cell RNA sequencing—that showed that deletion of the histone variants H3.V and H4.V increases antigen-gene clustering, DNA accessibility across sites of antigen expression and switching of the expressed antigen isoform, via homologous recombination. Our analyses identify histone variants as a molecular link between global genome architecture, local chromatin conformation and antigenic variation. KW - histone variants KW - genome architecture KW - single molecule real time (SMRT) KW - brucei genome KW - distance-dependent decay Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-224265 VL - 563 ER - TY - JOUR A1 - Bruchhagen, Christin A1 - Jarick, Marcel A1 - Mewis, Carolin A1 - Hertlein, Tobias A1 - Niemann, Silke A1 - Ohlsen, Knut A1 - Peters, Georg A1 - Planz, Oliver A1 - Ludwig, Stephan A1 - Ehrhardt, Christina T1 - Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound JF - Scientific Reports N2 - Influenza virus (IV) infections cause severe respiratory illnesses that can be complicated by bacterial super-infections. Previously, we identified the cellular Raf-MEK-ERK cascade as a promising antiviral target. Inhibitors of MEK, such as CI-1040, showed potent antiviral activity. However, it remained unclear if this inhibitor and its active form, ATR-002, might sensitize host cells to either IV or secondary bacterial infections. To address these questions, we studied the anti-pathogen activity of ATR-002 in comparison to CI-1040, particularly, its impact on Staphylococcus aureus (S. aureus), which is a major cause of IV super-infections. We analysed IV and S. aureus titres in vitro during super-infection in the presence and absence of the drugs and characterized the direct impact of ATR-002 on bacterial growth and phenotypic changes. Importantly, neither CI-1040 nor ATR-002 treatment led to increased bacterial titres during super-infection, indicating that the drug does not sensitize cells for bacterial infection. In contrast, we rather observed reduced bacterial titres in presence of ATR-002. Surprisingly, ATR-002 also led to reduced bacterial growth in suspension cultures, reduced stress- and antibiotic tolerance without resistance induction. Our data identified for the first time that a particular MEK-inhibitor metabolite exhibits direct antibacterial activity, which is likely due to interference with the bacterial PknB kinase/Stp phosphatase signalling system. KW - antimicrobials KW - pathogens Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-221648 VL - 8 ER - TY - JOUR A1 - Czimmerer, Zsolt A1 - Daniel, Bence A1 - Horvath, Attila A1 - Rückerl, Dominik A1 - Nagy, Gergely A1 - Kiss, Mate A1 - Peloquin, Matthew A1 - Budai, Marietta M. A1 - Cuaranta-Monroy, Ixchelt A1 - Simandi, Zoltan A1 - Steiner, Laszlo A1 - Nagy Jr., Bela A1 - Poliska, Szilard A1 - Banko, Csaba A1 - Bacso, Zsolt A1 - Schulman, Ira G. A1 - Sauer, Sascha A1 - Deleuze, Jean-Francois A1 - Allen, Judith E. A1 - Benko, Szilvia A1 - Nagy, Laszlo T1 - The Transcription Factor STAT6 Mediates Direct Repression of Inflammatory Enhancers and Limits Activation of Alternatively Polarized Macrophages JF - Immunity N2 - The molecular basis of signal-dependent transcriptional activation has been extensively studied in macrophage polarization, but our understanding remains limited regarding the molecular determinants of repression. Here we show that IL-4-activated STAT6 transcription factor is required for the direct transcriptional repression of a large number of genes during in vitro and in vivo alternative macrophage polarization. Repression results in decreased lineage-determining transcription factor, p300, and RNA polymerase II binding followed by reduced enhancer RNA expression, H3K27 acetylation, and chromatin accessibility. The repressor function of STAT6 is HDAC3 dependent on a subset of IL-4-repressed genes. In addition, STAT6-repressed enhancers show extensive overlap with the NF-κB p65 cistrome and exhibit decreased responsiveness to lipopolysaccharide after IL-4 stimulus on a subset of genes. As a consequence, macrophages exhibit diminished inflammasome activation, decreased IL-1β production, and pyroptosis. Thus, the IL-4-STAT6 signaling pathway establishes an alternative polarization-specific epigenenomic signature resulting in dampened macrophage responsiveness to inflammatory stimuli. KW - IL-4 KW - STAT6 KW - alternative macrophage polarization KW - transcription KW - repression KW - inflammation KW - inflammasome activation KW - pyroptosis KW - IL-1β KW - macrophage epigenomics Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-223380 VL - 48 ER - TY - JOUR A1 - Sunkavalli, Ushasree A1 - Aguilar, Carmen A1 - Silva, Ricardo Jorge A1 - Sharan, Malvika A1 - Cruz, Ana Rita A1 - Tawk, Caroline A1 - Maudet, Claire A1 - Mano, Miguel A1 - Eulalio, Ana T1 - Analysis of host microRNA function uncovers a role for miR-29b-2-5p in Shigella capture by filopodia JF - PLoS Pathogens N2 - MicroRNAs play an important role in the interplay between bacterial pathogens and host cells, participating as host defense mechanisms, as well as exploited by bacteria to subvert host cellular functions. Here, we show that microRNAs modulate infection by Shigella flexneri, a major causative agent of bacillary dysentery in humans. Specifically, we characterize the dual regulatory role of miR-29b-2-5p during infection, showing that this microRNA strongly favors Shigella infection by promoting both bacterial binding to host cells and intracellular replication. Using a combination of transcriptome analysis and targeted high-content RNAi screening, we identify UNC5C as a direct target of miR-29b-2-5p and show its pivotal role in the modulation of Shigella binding to host cells. MiR-29b-2-5p, through repression of UNC5C, strongly enhances filopodia formation thus increasing Shigella capture and promoting bacterial invasion. The increase of filopodia formation mediated by miR-29b-2-5p is dependent on RhoF and Cdc42 Rho-GTPases. Interestingly, the levels of miR-29b-2-5p, but not of other mature microRNAs from the same precursor, are decreased upon Shigella replication at late times post-infection, through degradation of the mature microRNA by the exonuclease PNPT1. While the relatively high basal levels of miR-29b-2-5p at the start of infection ensure efficient Shigella capture by host cell filopodia, dampening of miR-29b-2-5p levels later during infection may constitute a bacterial strategy to favor a balanced intracellular replication to avoid premature cell death and favor dissemination to neighboring cells, or alternatively, part of the host response to counteract Shigella infection. Overall, these findings reveal a previously unappreciated role of microRNAs, and in particular miR-29b-2-5p, in the interaction of Shigella with host cells. KW - hos tcells KW - Salmonellosis KW - Shigellosis KW - microRNAs KW - Shigella KW - small interfering RNAs KW - HeLa cells KW - Cell binding Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-158204 VL - 13 IS - 4 ER - TY - THES A1 - Oesterreich, Babett T1 - Preclinical development of an immunotherapy against antibiotic-resistant Staphylococcus aureus T1 - Präklinische Entwicklung einer Immuntherapie zur Behandlung Antibiotika-resistenter Staphylococcus aureus N2 - The Gram-positive bacterium Staphylococcus aureus is the leading cause of nosocomial infections. In particular, diseases caused by methicillin-resistant S. aureus (MRSA) are associated with higher morbidity, mortality and medical costs due to showing resistance to several classes of established antibiotics and their ability to develop resistance mechanisms against new antibiotics rapidly. Therefore, strategies based on immunotherapy approaches have the potential to close the gap for an efficient treatment of MRSA. In this thesis, a humanized antibody specific for the immunodominant staphylococcal antigen A (IsaA) was generated and thoroughly characterized as potential candidate for an antibody based therapy. A murine monoclonal antibody was selected for humanization based on its binding characteristics and the ability of efficient staphylococcal killing in mouse infection models. The murine antibody was humanized by CDR grafting and mouse and humanized scFv as well as scFv-Fc fragments were constructed for comparative binding studies to analyse the successful humanization. After these studies, the full antibody with the complete Fc region was constructed as isotype IgG1, IgG2 and IgG4, respectively to assess effector functions, including antibody-dependent killing of S. aureus. The biological activity of the humanized antibody designated hUK-66 was analysed in vitro with purified human PMNs and whole blood samples taken from healthy donors and patients at high risk of S. aureus infections, such as those with diabetes, end-stage renal disease, or artery occlusive disease (AOD). Results of the in vitro studies show, that hUK-66 was effective in antibody-dependent killing of S. aureus in blood from both healthy controls and patients vulnerable to S. aureus infections. Moreover, the biological activity of hUK-66 and hUK-66 combined with a humanized anti-alpha-toxin antibody (hUK-tox) was investigated in vivo using a mouse pneumonia model. The in vivo results revealed the therapeutic efficacy of hUK-66 and the antibody combination of hUK-66 and hUK-tox to prevent staphylococcal induced pneumonia in a prophylactic set up. Based on the experimental data, hUK-66 represents a promising candidate for an antibody-based therapy against antibiotic resistant MRSA. N2 - Staphylococcus aureus ist ein bedeutender nosokomialer Erreger, der eine Vielzahl von Infektionen im Menschen verursacht. Besonders Krankheiten, die durch Methicillin resistente S. aureus (MRSA) verursacht werden, sind mit einer erhöhten Morbidität, einer höheren Sterblichkeitsrate und hohen medizinischen Kosten verbunden. Seine besondere medizinische Bedeutung erlangte S. aureus durch die Ausbildung von Resistenzen gegen eine Vielzahl von Antibiotika und seiner Fähigkeit auch gegen neu entwickelte Antibiotika schnell Resistenzmechanismen auszubilden. Aus diesem Grund, ist die Entwicklung von neuen Therapieansätzen von besonderer Bedeutung, um die entstandene Lücke für eine effektive MRSA-Therapie zu schließen. In dieser Arbeit wurde ein humanisierter monoklonaler Antikörper entwickelt und charakterisiert, der spezifisch an das „immunodominant staphylococcal antigen A“ (IsaA) bindet. Dieser Antiköper wurde auf Grund seiner Eigenschaft, in einem Mausmodell effektiv S. aureus abzutöten, als vielversprechender Kandidat für eine Antikörper-Therapie ausgewählt. Der murine Vorläuferantikörper wurde mittels „CDR grafting“ humanisiert und durch die Generierung von humanisierten und murinen scFv und scFv-Fc Fragmenten, die in vergleichenden Bindungsstudien getestet wurden, konnte der Erfolg der Humanisierung beurteilt werden. Im Anschluss wurde der vollständige Antikörper mit vollständig funktionaler Fc-Region in den Isotypen IgG1, IgG2 und IgG4 hergestellt. Die Funktionalität des humanisierten Antikörpers wurde in vitro mittels aufgereinigter PMNs und Blutproben von gesunden Spendern und Patienten bestimmt, die ein hohes Risiko für S. aureus Infektionen besitzen wie Diabetiker, Dialyse-Patienten und Patienten mit arterieller Verschlusskrankheit. Die Ergebnisse der in vitro-Studien zeigen, dass der anti-IsaA-Antikörper hUK-66 nicht nur S. aureus effektiv in Blutproben von gesunden Spendern abtötet, sondern auch in Blutproben von Patienten mit erhöhter Anfälligkeit für S. aureus Infektionen. Darüber hinaus wurde die biologische Aktivität des humanisierten Antikörpers gegen IsaA als Monotherapie und in Kombination mit einem humanisierten anti-alpha-Toxin-Antikörper (hUK-tox) in vivo in einem Maus Pneumonie Modell untersucht. Hierbei konnte gezeigt werden, dass die prophylaktische Verabreichung von hUK-66 sowie die Kombination von hUK-66 und hUK-tox, die Bildung einer Staphylokokken-induzierten Pneumonie mit Todesfolge signifikant senkt. KW - Staphylococcus KW - Immunotherapy Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123237 ER - TY - THES A1 - Sharan, Malvika T1 - Bio-computational identification and characterization of RNA-binding proteins in bacteria T1 - Bioinformatische Identifikation und Charakterisierung von RNA-bindenden Proteinen in Bakterien N2 - RNA-binding proteins (RBPs) have been extensively studied in eukaryotes, where they post-transcriptionally regulate many cellular events including RNA transport, translation, and stability. Experimental techniques, such as cross-linking and co-purification followed by either mass spectrometry or RNA sequencing has enabled the identification and characterization of RBPs, their conserved RNA-binding domains (RBDs), and the regulatory roles of these proteins on a genome-wide scale. These developments in quantitative, high-resolution, and high-throughput screening techniques have greatly expanded our understanding of RBPs in human and yeast cells. In contrast, our knowledge of number and potential diversity of RBPs in bacteria is comparatively poor, in part due to the technical challenges associated with existing global screening approaches developed in eukaryotes. Genome- and proteome-wide screening approaches performed in silico may circumvent these technical issues to obtain a broad picture of the RNA interactome of bacteria and identify strong RBP candidates for more detailed experimental study. Here, I report APRICOT (“Analyzing Protein RNA Interaction by Combined Output Technique”), a computational pipeline for the sequence-based identification and characterization of candidate RNA-binding proteins encoded in the genomes of all domains of life using RBDs known from experimental studies. The pipeline identifies functional motifs in protein sequences of an input proteome using position-specific scoring matrices and hidden Markov models of all conserved domains available in the databases and then statistically score them based on a series of sequence-based features. Subsequently, APRICOT identifies putative RBPs and characterizes them according to functionally relevant structural properties. APRICOT performed better than other existing tools for the sequence-based prediction on the known RBP data sets. The applications and adaptability of the software was demonstrated on several large bacterial RBP data sets including the complete proteome of Salmonella Typhimurium strain SL1344. APRICOT reported 1068 Salmonella proteins as RBP candidates, which were subsequently categorized using the RBDs that have been reported in both eukaryotic and bacterial proteins. A set of 131 strong RBP candidates was selected for experimental confirmation and characterization of RNA-binding activity using RNA co-immunoprecipitation followed by high-throughput sequencing (RIP-Seq) experiments. Based on the relative abundance of transcripts across the RIP-Seq libraries, a catalogue of enriched genes was established for each candidate, which shows the RNA-binding potential of 90% of these proteins. Furthermore, the direct targets of few of these putative RBPs were validated by means of cross-linking and co-immunoprecipitation (CLIP) experiments. This thesis presents the computational pipeline APRICOT for the global screening of protein primary sequences for potential RBPs in bacteria using RBD information from all kingdoms of life. Furthermore, it provides the first bio-computational resource of putative RBPs in Salmonella, which could now be further studied for their biological and regulatory roles. The command line tool and its documentation are available at https://malvikasharan.github.io/APRICOT/. N2 - RNA-bindende Proteine (RBPs) wurden umfangreich in Eukaryoten erforscht, in denen sie viele Prozesse wie RNA-Transport, -Translation und -Stabilität post-transkriptionell regulieren. Experimentelle Methoden wie Cross-linking and Koimmunpräzipitation mit nachfolgedener Massenspektromentrie / RNA-Sequenzierung ermöglichten eine weitreichende Charakterisierung von RBPs, RNA-bindenden Domänen (RBDs) und deren regulatorischen Rollen in eukaryotischen Spezies wie Mensch und Hefe. Weitere Entwicklungen im Bereich der hochdurchsatzbasierten Screeningverfahren konnten das Verständnis von RBPs in Eukaryoten enorm erweitern. Im Gegensatz dazu ist das Wissen über die Anzahl und die potenzielle Vielfalt von RBPs in Bakterien dürftig. In der vorliegenden Arbeit präsentiere ich APRICOT, eine bioinformatische Pipeline zur sequenzbasierten Identifikation und Charakterisierung von Proteinen aller Domänen des Lebens, die auf RBD-Informationen aus experimentellen Studien aufbaut. Die Pipeline nutzt Position Specific Scoring Matrices und Hidden-MarkovModelle konservierter Domänen, um funktionelle Motive in Proteinsequenzen zu identifizieren und diese anhand von sequenzbasierter Eigenschaften statistisch zu bewerten. Anschließend identifiziert APRICOT mögliche RBPs und charakterisiert auf Basis ihrer biologischeren Eigenschaften. In Vergleichen mit ähnlichen Werkzeugen übertraf APRICOT andere Programme zur sequenzbasierten Vorhersage von RBPs. Die Anwendungsöglichkeiten und die Flexibilität der Software wird am Beispiel einiger großer RBP-Kollektionen, die auch das komplette Proteom von Salmonella Typhimurium SL1344 beinhalten, dargelegt. APRICOT identifiziert 1068 Proteine von Salmonella als RBP-Kandidaten, die anschließend unter Nutzung der bereits bekannten bakteriellen und eukaryotischen RBDs klassifiziert wurden. 131 der RBP-Kandidaten wurden zur Charakterisierung durch RNA co-immunoprecipitation followed by high-throughput sequencing (RIP-seq) ausgewählt. Basierend auf der relativen Menge an Transkripten in den RIP-seq-Bibliotheken wurde ein Katalog von angereicherten Genen erstellt, der auf eine potentielle RNA-bindende Funktion in 90% dieser Proteine hindeutet. Weiterhin wurden die Bindungstellen einiger dieser möglichen RBPs mit Cross-linking and Co-immunoprecipitation (CLIP) bestimmt. Diese Doktorarbeit beschreibt die bioinformatische Pipeline APRICOT, die ein globales Screening von RBPs in Bakterien anhand von Informationen bekannter RBDs ermöglicht. Zudem enthält sie eine Zusammenstellung aller potentieller RPS in Salmonella, die nun auf ihre biologsche Funktion hin untersucht werden können. Das Kommondozeilen-Programm und seine Dokumentation sind auf https://malvikasharan.github.io/APRICOT/ verfügbar. KW - Bioinformatics Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-153573 ER - TY - JOUR A1 - Hampe, Irene A. I. A1 - Friedman, Justin A1 - Edgerton, Mira A1 - Morschhäuser, Joachim T1 - An acquired mechanism of antifungal drug resistance simultaneously enables Candida albicans to escape from intrinsic host defenses JF - PLoS Pathogens N2 - The opportunistic fungal pathogen Candida albicans frequently produces genetically altered variants to adapt to environmental changes and new host niches in the course of its life-long association with the human host. Gain-of-function mutations in zinc cluster transcription factors, which result in the constitutive upregulation of their target genes, are a common cause of acquired resistance to the widely used antifungal drug fluconazole, especially during long-term therapy of oropharyngeal candidiasis. In this study, we investigated if C. albicans also can develop resistance to the antimicrobial peptide histatin 5, which is secreted in the saliva of humans to protect the oral mucosa from pathogenic microbes. As histatin 5 has been shown to be transported out of C. albicans cells by the Flu1 efflux pump, we screened a library of C. albicans strains that contain artificially activated forms of all zinc cluster transcription factors of this fungus for increased FLU1 expression. We found that a hyperactive Mrr1, which confers fluconazole resistance by upregulating the multidrug efflux pump MDR1 and other genes, also causes FLU1 overexpression. Similarly to the artificially activated Mrr1, naturally occurring gain-of-function mutations in this transcription factor also caused FLU1 upregulation and increased histatin 5 resistance. Surprisingly, however, Mrr1-mediated histatin 5 resistance was mainly caused by the upregulation of MDR1 instead of FLU1, revealing a previously unrecognized function of the Mdr1 efflux pump. Fluconazole-resistant clinical C. albicans isolates with different Mrr1 gain-of-function mutations were less efficiently killed by histatin 5, and this phenotype was reverted when MRR1 was deleted. Therefore, antimycotic therapy can promote the evolution of strains that, as a consequence of drug resistance mutations, simultaneously have acquired increased resistance against an innate host defense mechanism and are thereby better adapted to certain host niches. KW - antimicrobial resistance KW - transcriptional control KW - Candida albicans KW - transcription factors KW - mutation KW - hyperexpression techniques KW - antifungals KW - point mutation Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-158883 VL - 13 IS - 9 ER -